

November 04, 2025

Head- Listing & Compliance

Metropolitan Stock Exchange of India Ltd. (MSEI),

205(A), 2nd Floor, Piramal Agastya Corporate Park,

Kamani Junction, LBS Road,

Kurla (West),

Mumbai – 400 070

Subject: Outcome of Board Meeting held on November 04, 2025- Un-audited Financial Results for the quarter and half Year ended September 30, 2025

Dear Sir,

This is to inform that the Board of Directors of the Company at its meeting held today, i.e. November 04, 2025, which commenced at 02.30 p.m. and concluded at 03.00 p.m. has, inter-alia, transacted the following business: -

1. Approved and taken on record the Standalone Un-audited Financial Results along with Limited Review Report of the Company for the quarter and half year ended on September 30, 2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (enclosed herewith),
2. Taken on record the Limited Review Report of M/s. Rajesh U Shah & Associates, Chartered Accountants for the quarter and half year ended on September 30, 2025;

Kindly take the above information on your record.

Thanking You,

Yours sincerely,


For Jagadishwar Pharmaceutical Works Limited

Swapan Sarkar

(SWAPAN SARKAR)

Director

DIN: 05149442



Encl.: As above

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232WB1987PLC281952)

21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Email: jpwtd@yahoo.com, Website: jagadishwarpharma.com, Tel.: +91 9163513015

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

(Rs. In Lacs)

	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income From Operations						
	(a) Net Sales / Income from Operations (Net of Excise Duty)	5.981	-	-	5.981	-	-
	(b) Other Operating Income	9.011	9.077	5.992	18.088	15.069	25.080
	Total Income from Operations	14.992	9.077	5.992	24.069	15.069	25.080
2	Expenses						
	(a) Cost of materials consumed	5.981	-	-	5.981	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	12.325
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	(12.325)
	(d) Employee benefits expense	13.034	7.319	13.039	20.353	20.359	35.128
	(e) Depreciation and amortisation expense	-	-	-	-	-	0.166
	(f) Other expenses	1.208	4.175	1.350	5.383	5.525	8.674
	Total Expenses	20.224	11.494	14.389	31.718	25.884	43.968
	Profit / (Loss) from Operations before other income, finance costs and exceptional items (1-2)	(5.231)	(2.418)	(8.398)	(7.649)	(10.815)	(18.888)
3	Other Income	-	-	-	-	-	-
4	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)	(5.231)	(2.418)	(8.398)	(7.649)	(10.815)	(18.888)
5	Finance Costs	-	-	-	-	-	-
6	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(5.231)	(2.418)	(8.398)	(7.649)	(10.815)	(18.888)
7	Exceptional Items	-	-	-	-	-	-
8	Profit / (Loss) from ordinary activities before tax (7-8)	(5.231)	(2.418)	(8.398)	(7.649)	(10.815)	(18.888)
9	Tax Expense	-	-	-	-	-	-
10	Net Profit / (Loss) from ordinary activities after tax (9-10)	(5.231)	(2.418)	(8.398)	(7.649)	(10.815)	(18.888)
11	Extraordinary items (net of tax Rs. Nil Lakhs)	-	-	-	-	-	-
12	Net Profit / (Loss) for the period (11-12)	(5.231)	(2.418)	(8.398)	(7.649)	(10.815)	(18.888)
13	Share of Profit / (loss) of associates	-	-	-	-	-	-
14	Minority Interest	-	-	-	-	-	-
15	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13-14-15)	(5.231)	(2.418)	(8.398)	(7.649)	(10.815)	(18.888)
16	Other Comprehensive Income	-	-	-	-	-	12.271
17	Total Comprehensive Income	(5.231)	(2.418)	(8.398)	(7.649)	(10.815)	(6.617)
18	Paid-up Equity Share Capital (Face Value of Rs.10/- per Share)	2,970.019	2,970.019	2,970.019	2,970.019	2,970.019	2,970.019
19	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	138.953
20	Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)	-	-	-	-	-	-
21.i	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
21.ii	Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)	-	-	-	-	-	-
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-

Notes:

- The above results are in compliance with Indian Accounting Standards (Ind-AS) notified by the Ministry of Corporate Affairs. The results for the previous periods have been restated as per Ind AS. The standalone financial results of the Company for the Quarter and Half Year ended 30th September, 2025 have been reviewed by the Audit Committee at their meeting held on 04th November, 2025 and have been approved by the Board of Directors at its meeting held on 04th November, 2025.
- The Statutory Auditors have carried out a "Limited Review" of the above financial results for the Quarter / Half Year ended 30th September, 2025.
- Previous period/Year figures have been regrouped/reclassified to make them comparable with those of current period/year.

For Jagadishwar Pharmaceutical Works Limited


Swapan Sarkar
Director
(DIN : 05149442)

Place : Kolkata
Date : 04.11.2025

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232WB1987PLC281952)

21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Standalone Statement of Assets and Liabilities

(Rs. In Lacs)

Sr No	Particulars	Current Half Year ended 30th September, 2025 (Unaudited)	Previous Year ended 31st March, 2025 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	2,970.02	2,970.02
	(b) Reserves and Surplus	124.69	132.34
	(c) Money received against share warrants	-	-
	Sub-total - Shareholder's funds	3,094.71	3,102.35
2	Share Application Money - pending allotment	-	-
3	Minority interest	-	-
4	Non-Current Liabilities		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	(c) Other long-term liabilities	-	-
	(d) Long-term provisions	-	-
	Sub-total - Non-Current Liabilities	-	-
5	Current Liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	-	-
	(c) Other current liabilities	5.70	2.47
	(d) Short-term provisions	-	-
	Sub-total - Current Liabilities	5.70	2.47
	TOTAL - EQUITY AND LIABILITIES	3,100.41	3,104.82
B	ASSETS		
1	Non-Current Assets		
	(a) Fixed assets	0.10	0.10
	(b) Goodwill on consolidation	-	-
	(c) Non-current investments	1,336.50	1,336.50
	(d) Deferred tax assets (net)	-	-
	(e) Long-term loans and advances	5.64	3.83
	(f) Other non-current assets	-	-
	Sub-total - Non-Current Assets	1,342.24	1,340.43
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	439.40	445.38
	(c) Trade receivables	-	-
	(d) Cash and cash equivalents	4.88	2.25
	(e) Short-term loans and advances	283.11	290.69
	(f) Other current assets	1,030.77	1,026.07
	Sub-total - Current Assets	1,758.16	1,764.39
	TOTAL - ASSETS	3,100.41	3,104.82

For Jagadishwar Pharmaceutical Works Limited



Swapan Sarkar

Director

(DIN : 05149442)

Place: Kolkata

Date : 04.11.2025

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232WB1987PLC281952)

21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Cash Flow Statement for the Half Year ended September 30, 2025

(Rs. In Lacs)

	Half Year Ended 30th September, 2025 (Unaudited)	Previous Year Ended 31st March, 2025 (Audited)
A. Cash Flow From Operating Activities		
Net Profit before taxation	(7.65)	(18.89)
Add: Depreciation	-	0.17
Add: Interest Expenses	-	-
Add: Loss on sale of Fixed Asset	-	-
Add: Loss on sale of Investments	-	-
Less :Interest Income	(18.09)	(25.08)
Operating Profit before Working Capital Changes	(25.74)	(43.80)
Adjustment for:		
Non Current Financial Assets	-	-
Other Non Current Assets	-	-
Inventories	5.98	(12.33)
Trade receivable	-	-
Other Current Assets	(4.70)	25.77
Loans and Advances	7.58	-
Trade payable and other Liabilities	-	-
Other Financial Liabilities	-	-
Other Current liabilities	3.23	(0.08)
Net Cash inflow from/(outflow) from operating activities	(13.64)	(30.43)
B. Cash flow from Investing Activities		
Sale Proceeds from fixed Assets	-	-
Sale Proceeds from Investments	-	-
Interest received	18.09	25.08
Fixed Assets Purchase	-	-
Income tax	(1.81)	0.45
Net Cash inflow from/(outflow) from Investing Activities	16.28	25.53
C. Cash flow from Financing Activities		
Proceeds from Borrowing	-	-
Interest paid	-	-
Dividend Paid	-	-
Net Cash inflow from/(outflow) from Financing Activities	-	-
Net Increase /(decrease) in cash and Cash Equivalents	2.63	(4.91)
Opening Cash and Cash Equivalents	2.25	7.16
Closing Cash and Cash Equivalents	4.88	2.25

For Jagadishwar Pharmaceutical Works Limited



Swapan Sarkar
Swapan Sarkar
 Director
 (DIN : 05149442)

Place : Kolkata

Date : 04.11.2025



Review report to Jagadishwar Pharmaceutical Works Limited

We have reviewed the accompanying statement of unaudited financial results of Jagadishwar Pharmaceutical Works Limited (Name of the Company) for the period ended 30th September 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.



For Rajesh U Shah & Associates
Chartered Accountants


Rajesh Shah

Proprietor

Membership Number: 056550

Firm Regn. No.: 327799E

UDIN: 25056550BM0MCI5363

Place: Kolkata

Date: November 04, 2025